Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans.
Brücher R., Cifuentes M., Acuña MJ., Albala C., Rojas CV.
Laboratory Study, published in Obesity (Silver Spring) (2007) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Obesity (Silver Spring) (2007)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 17636081
- DOI
- 10.1038/oby.2007.196
Abstract (original English)
The ability to form new adipose cells is important to adipose tissue physiology; however, the mechanisms controlling the recruitment of adipocyte progenitors are poorly understood. A role for locally generated angiotensin II in this process is currently proposed. Given that visceral adipose tissue reportedly expresses higher levels of angiotensinogen compared with other depots and the strong association of augmented visceral fat mass with the adverse consequences of obesity, we studied the role of angiotensin II in regulating adipogenic differentiation in omental fat of obese and non-obese humans. The angiotensin II effect on adipose cell formation was evaluated in human omental adipocyte progenitor cells that were stimulated to adipogenic differentiation in vitro. The adipogenic response was measured by the activity of the differentiation marker glycerol-3-phosphate dehydrogenase. Angiotensin II reduced the adipogenic response of adipocyte progenitor cells, and the extent of the decrease correlated directly with the subjects' BMI (p=0.01, R2=0.30). A 56.3+/-3.4% and 44.5+/-2.7% reduction of adipogenesis was found in obese and non-obese donors' cells, respectively (p<0.01). The effect of angiotensin II was reversed by type 1 angiotensin receptor antagonist losartan. A greater anti-adipogenic response to angiotensin II in omental adipose progenitor cells from obese subjects open
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.